Literature DB >> 18403936

Evaluation of the French national plan to promote screening and early management of viral hepatitis C, between 1997 and 2003: a comparative cross-sectional study in Poitou-Charentes region.

Gautier Defossez1, Alain Verneau, Isabelle Ingrand, Christine Silvain, Pierre Ingrand, Michel Beauchant.   

Abstract

BACKGROUND AND AIMS: The aim of this repeated cross-sectional survey was to document trends in screening practices, to analyze the evolution of the epidemiological characteristics of patients with newly diagnosed hepatitis C virus (HCV) infection, and to evaluate the implementation of hepatitis C management guidelines.
METHODS: Medical laboratories in Poitou-Charentes region were surveyed on serological tests for HCV infection prescribed during two 2-month periods in 1997 and 2000, and a 4-month period in 2003. An epidemiological questionnaire and a 12-month follow-up questionnaire were addressed to physicians who prescribed tests that were positive.
RESULTS: The annual screening coverage rate increased by 40% during the study period, whereas the number of positive tests fell by 53%. The estimated detection rate of new cases decreased from 43 to 26 per 100 000 inhabitants between 1997 and 2003. In 2003, 56% of serological tests were prescribed to patients who already knew that they were HCV-seropositive. The frequencies of the two main risk factors (transfusion and intravenous drug use) slightly decreased. Management of newly diagnosed patients was inappropriate in 42% of cases in 1997, 33% in 2000, and 34% in 2003; 26% of the participants at the three periods declined follow-up. Among drug users, the proportion of treated patients remained stable (17%). One-third of the drug users were lost to follow-up by their family doctor.
CONCLUSION: Campaigns to encourage HCV screening have been effective, but the number of newly diagnosed cases has fallen markedly. National campaigns targeting the general public and healthcare professionals seem to have had no impact on patient management: in particular, drug users still do not receive adequate follow-up.

Entities:  

Mesh:

Year:  2008        PMID: 18403936     DOI: 10.1097/MEG.0b013e3282f479ab

Source DB:  PubMed          Journal:  Eur J Gastroenterol Hepatol        ISSN: 0954-691X            Impact factor:   2.566


  9 in total

1.  A Canadian screening program for hepatitis C: is now the time?

Authors:  Hemant A Shah; Jenny Heathcote; Jordan J Feld
Journal:  CMAJ       Date:  2013-09-30       Impact factor: 8.262

Review 2.  Epidemiology and natural history of HCV infection.

Authors:  Behzad Hajarizadeh; Jason Grebely; Gregory J Dore
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-07-02       Impact factor: 46.802

Review 3.  A systematic review of Hepatitis C virus treatment uptake among people who inject drugs in the European Region.

Authors:  Jeffrey V Lazarus; Ida Sperle; Mojca Maticic; Lucas Wiessing
Journal:  BMC Infect Dis       Date:  2014-09-19       Impact factor: 3.090

Review 4.  Hepatitis C virus infection epidemiology among people who inject drugs in Europe: a systematic review of data for scaling up treatment and prevention.

Authors:  Lucas Wiessing; Marica Ferri; Bart Grady; Maria Kantzanou; Ida Sperle; Katelyn J Cullen; Angelos Hatzakis; Maria Prins; Peter Vickerman; Jeffrey V Lazarus; Vivian D Hope; Catharina Matheï
Journal:  PLoS One       Date:  2014-07-28       Impact factor: 3.240

Review 5.  Targeted hepatitis C antibody testing interventions: a systematic review and meta-analysis.

Authors:  Esther Jane Aspinall; Joseph Samuel Doyle; Stephen Corson; Margaret Elena Hellard; David Hunt; David Goldberg; Tim Nguyen; Yngve Falck-Ytter; Rebecca Lynn Morgan; Bryce Smith; Mark Stoove; Stefan Zbyszko Wiktor; Sharon Hutchinson
Journal:  Eur J Epidemiol       Date:  2014-11-11       Impact factor: 8.082

6.  A before and after cross-sectional analysis of a public health campaign to increase kidney health awareness in a Canadian province.

Authors:  Krista Ryz; Navdeep Tangri; Mauro Verrelli; Jan Schneider; Amie Lesyk; Amanda Eng; Brett Hiebert; Reid H Whitlock; Manish M Sood; Claudio Rigatto; Paul Komenda
Journal:  BMC Res Notes       Date:  2015-11-20

Review 7.  Are the testing needs of key European populations affected by hepatitis B and hepatitis C being addressed? A scoping review of testing studies in Europe.

Authors:  Jeffrey V Lazarus; Ida Sperle; Alexander Spina; Jürgen K Rockstroh
Journal:  Croat Med J       Date:  2016-10-31       Impact factor: 1.351

8.  Survey of programmatic experiences and challenges in delivery of hepatitis B and C testing in low- and middle-income countries.

Authors:  Azumi Ishizaki; Julie Bouscaillou; Niklas Luhmann; Stephanie Liu; Raissa Chua; Nick Walsh; Sarah Hess; Elena Ivanova; Teri Roberts; Philippa Easterbrook
Journal:  BMC Infect Dis       Date:  2017-11-01       Impact factor: 3.090

9.  Hepatitis B and C testing strategies in healthcare and community settings in the EU/EEA: A systematic review.

Authors:  Lauren M K Mason; Irene K Veldhuijzen; Erika Duffell; Ayla van Ahee; Eveline M Bunge; Andrew J Amato-Gauci; Lara Tavoschi
Journal:  J Viral Hepat       Date:  2019-08-16       Impact factor: 3.728

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.